Tag Archives: HPV

Antibody Responses to Quadrivalent HPV Vaccination in HIV-Infected Young Women

Abstract: We compared antibody responses of HIV-infected young women to the human papillomavirus (HPV) 6, 11, 16, and 18 vaccine using total immunoglobulin (Ig) G Luminex immunoassay (LIA) and competitive Luminex immunoassay (cLIA) assays.

Posted in HIV/AIDS, Infectious Disease, Journal Watch, Medications & Treatments, Research | Also tagged | Comments closed

African Governments Should Commit To Scaling-Up National HPV Immunization Programs

CNBC Africa: Op-Ed: Africa is now in serious danger of sleepwalking into a cancer crisis Ngozi Okonjo-Iweala, Board chair of Gavi, the Vaccine Alliance “…Currently 266,000 women die horrible deaths [from cervical cancer] every year — one every two minutes — of which 87 percent are in low- and middle-income countries, with the eight highest…More

Posted in Aid, Aid & Development, Cancer, Immunizations, Infectious Disease, Kaiser's Global Health Update, Maternal & Reproductive Health, Noncommunicable Disease, Women & Children | Also tagged , , | Comments closed

Barriers to HPV immunization among blacks and latinos: a qualitative analysis of caregivers,…

Despite recommendations that 11–12-year-olds receive the full three-shot Human papillomavirus (HPV) vaccine series, national HPV immunization coverage rates remain low.

Posted in Infectious Disease, Journal Watch, Vaccines | Also tagged | Comments closed

Global estimates of human papillomavirus vaccination coverage by region and income…

Many women from high-income and upper-middle-income countries have been vaccinated against HPV. However, populations with the highest incidence and mortality of disease remain largely unprotected. Rapid roll-out of the vaccine in low-income and middle-income countries might be the only feasible way to narrow present inequalities in cervical cancer burden and prevention.

Posted in Immunizations, Infectious Disease, Journal Watch, Vaccines | Also tagged | Comments closed

Feasibility and acceptability of delivering adolescent health interventions alongside HPV…

Background: Human papillomavirus (HPV) vaccination offers an opportunity to strengthen provision of adolescent health interventions (AHI).

Posted in Delivery, Journal Watch, Policy & Systems | Also tagged | Comments closed

Parental acceptance and uptake of the HPV vaccine among African-Americans and Latinos in the…

Publication date: June 2016 Source:Social Science & Medicine, Volume 159 Author(s): Kayoll V.

Posted in Cancer, Immunizations, Infant & Child Health, Infectious Disease, Journal Watch, Noncommunicable Disease, Vaccines, Women & Children | Also tagged | Comments closed

“Saving lives”: Adapting and adopting Human Papilloma Virus (HPV) vaccination in Austria

Publication date: March 2016 Source:Social Science & Medicine, Volume 153 Author(s): Katharina T.

Posted in Aid, Aid & Development, Delivery, Financing, Infectious Disease, Journal Watch, Policy & Systems, Politics, Universal Health Coverage, Vaccines | Also tagged | Comments closed

Current Global Pricing For Human Papillomavirus Vaccines Brings The Greatest Economic Benefits…

Vaccinating females against human papillomavirus (HPV) prior to the debut of sexual activity is an effective way to prevent cervical cancer, yet vaccine uptake in low- and middle-income countries has been hindered by high vaccine prices.

Posted in Infant & Child Health, Infectious Disease, Journal Watch, Maternal & Reproductive Health, Vaccines, Women & Children | Also tagged | Comments closed

Pilot study investigating the prevalence of oral Human Papilloma Viral (HPV) infection in young…

Head and neck squamous cell carcinomas (HNSCC) are the sixth most common type of cancer worldwide, with around 9000 HNSCC diagnosed within the UK/annum.1 Though around 60–75% of HNSCC are linked to smoking and/or alcohol, there is a subset of HNSCC caused by oral infection with the Human Papilloma Virus (HPV).2,3

Posted in Infectious Disease, Journal Watch, Men's Health, Women & Children | Tagged | Comments closed

Distribution of genital human papillomavirus genotypes in benign clinical manifestations among…

In the literature, data on the prevalence of human papillomavirus (HPV) infection in men vary significantly and the exact distribution of specific genotypes is still unclear.

Posted in Infectious Disease, Journal Watch, Maternal & Reproductive Health, Women & Children | Tagged | Comments closed

Cost- effectiveness of HPV vaccination regime: comparing twice versus thrice vaccinations dose…

The HPV vaccine was introduced to Malaysian national immunization programme in 2010.

Posted in Infectious Disease, Journal Watch, Maternal & Reproductive Health, Policy & Systems, Vaccines, Women & Children | Also tagged , | Comments closed

Brazil Lowers Number Of HPV, Pneumonia Vaccine Doses Available Through Public Health Service To…

Reuters: Brazil cuts vaccine doses as health system under pressure “Brazil has cut the number of doses for vaccinations given by the public health service to counter human papillomavirus (HPV) and pneumonia, as Latin America’s largest economy looks to reduce health costs in the midst of a deep recession. In a statement late Tuesday, the…More

Posted in Infant & Child Health, Infectious Disease, Kaiser's Global Health Update, Maternal & Reproductive Health, Vaccines, Women & Children | Also tagged , , | Comments closed

Implementation of a national school-based Human Papillomavirus (HPV) vaccine campaign in Fiji:…

In 2008 Fiji implemented a nationwide Human Papillomavirus (HPV) vaccine campaign targeting all girls aged 9–12 years through the existing school-based immunisation program.

Posted in Aid & Development, Family planning, Immunizations, Infant & Child Health, Infectious Disease, Journal Watch, Maternal & Reproductive Health, Vaccines, Women & Children | Tagged | Comments closed

Discounting role in cost-effectiveness of HPV vaccination by Starkie Camejo et al. (Public…

We thank Starkie Camejo and colleagues for highlighting the importance of the discount rate to the economic evaluation of public health interventions.1 There is a need to consider the impact of discounting for health investment decisions where costs are borne upfront and benefits accrued over the course of many years.

Posted in Infectious Disease, Journal Watch, Vaccines, Women & Children | Also tagged , | Comments closed